XGN VS SLS Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

XGN
10/100

XGN returned -48.68% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SLS
10/100

SLS returned -76.31% in the last 12 months. Based on SPY's performance of -20.72%, its performance is below average giving it a score of 10 of 100.

Sentiment

XGN
68/100

XGN had a bullish sentiment score of 68.07% across Twitter and StockTwits over the last 12 months. It had an average of 2.75 posts, 0.12 comments, and 0.25 likes per day.

SLS
70/100

SLS had a bullish sentiment score of 69.56% across Twitter and StockTwits over the last 12 months. It had an average of 77.08 posts, 457.69 comments, and 201.27 likes per day.

Technicals

XGN
14/100

XGN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

SLS
18/100

SLS receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

XGN
33/100

XGN has missed earnings 4 times in the last 20 quarters.

SLS
10/100

SLS has missed earnings 8 times in the last 20 quarters.

Profit

XGN
10/100

Out of the last 20 quarters, XGN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SLS
10/100

Out of the last 20 quarters, SLS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

XGN
52/100

XGN has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

SLS
52/100

SLS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

XGN

"Dividend" not found for XGN

SLS
10/100

SLS's most recent dividend was $1.07 per share, based on a share price of $0.94. It was a payout ratio of -3.98% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Exagen Inc. Common Stock Summary

Nasdaq / XGN
Healthcare
Medical - Diagnostics & Research
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

SELLAS Life Sciences Group, Inc. Common Stock Summary

Nasdaq / SLS
Healthcare
Biotechnology
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.